{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:10:07Z","timestamp":1791112207506,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1016\/j.ejphar.2007.03.021","type":"journal-article","created":{"date-parts":[[2007,3,27]],"date-time":"2007-03-27T07:16:30Z","timestamp":1174979790000},"page":"94-102","source":"Crossref","is-referenced-by-count":72,"title":["Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: Acute and subchronic studies in rats"],"prefix":"10.1016","volume":"566","author":[{"given":"Elisabetta","family":"Tronci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Simola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Borsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Schintu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Frau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Carminati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micaela","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2007.03.021_bib1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1212\/01.WNL.0000073136.00548.D4","article-title":"Adenosine A(2A) receptor antagonist treatment of Parkinson's disease","volume":"61","author":"Bara-Jimenez","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2007.03.021_bib2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0014-4886(03)00250-4","article-title":"A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease","volume":"184","author":"Bibbiani","year":"2003","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejphar.2007.03.021_bib3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1471-4159.1990.tb08817.x","article-title":"Both A1 and A2a purine receptors regulate striatal acetylcholine release","volume":"55","author":"Brown","year":"1990","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2007.03.021_bib4","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/syn.10066","article-title":"Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent l-dopa and A2A receptor blockade plus l-dopa in dopamine-denervated rats","volume":"44","author":"Carta","year":"2002","journal-title":"Synapse"},{"key":"10.1016\/j.ejphar.2007.03.021_bib5","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/00008877-200609000-00005","article-title":"How reliable is the behavioural evaluation of dyskinesia in animal models of Parkinson's disease?","volume":"17","author":"Carta","year":"2006","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.ejphar.2007.03.021_bib6","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1046\/j.1460-9568.1998.00285.x","article-title":"l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA","volume":"10","author":"Cenci","year":"1998","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejphar.2007.03.021_bib7","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1212\/01.WNL.0000095223.08711.48","article-title":"Translating A2A antagonist KW6002 from animal models to parkinsonian patients","volume":"61","author":"Chase","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2007.03.021_bib8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0166-4328(03)00178-5","article-title":"The adenosine A2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism","volume":"148","author":"Correa","year":"2004","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejphar.2007.03.021_bib9","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.bbr.2003.10.009","article-title":"Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias","volume":"152","author":"Delfino","year":"2004","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejphar.2007.03.021_bib10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0014-2999(96)00944-2","article-title":"Adenosine A2A receptor antagonism potentiates l-DOPA induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats","volume":"321","author":"Fenu","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2007.03.021_bib11","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S0166-2236(97)01096-5","article-title":"Adenosine\u2013dopamine receptor\u2013receptor interactions as an integrative mechanism in the basal ganglia","volume":"20","author":"Ferr\u00e9","year":"1997","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.ejphar.2007.03.021_bib12","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1212\/WNL.52.8.1673","article-title":"Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys","volume":"52","author":"Grondin","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2007.03.021_bib13","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1212\/01.WNL.0000081227.84197.0B","article-title":"Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD","volume":"61","author":"Hauser","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2007.03.021_bib14","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1006\/exnr.1998.6819","article-title":"Characterization of enhanced behavioral responses to l-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease","volume":"151","author":"Henry","year":"1998","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejphar.2007.03.021_bib15","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1006\/exnr.1998.6996","article-title":"Effect of repeated l-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat","volume":"155","author":"Henry","year":"1999","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejphar.2007.03.021_bib16","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0014-4886(03)00064-5","article-title":"Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease","volume":"183","author":"Henry","year":"2003","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejphar.2007.03.021_bib17","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1212\/01.WNL.0000095209.59347.79","article-title":"A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD","volume":"61","author":"Jenner","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2007.03.021_bib18","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0006-8993(93)90925-D","article-title":"Adenosine receptor antagonists potentiate dopamine receptor agonist-induced rotational behavior in 6-hydroxydopamine-lesioned rats","volume":"613","author":"Jiang","year":"1993","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2007.03.021_bib19","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1006\/exnr.2000.7350","article-title":"Combined use of the adenosine A(2A) antagonist KW-6002 with l-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys","volume":"162","author":"Kanda","year":"2000","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejphar.2007.03.021_bib20","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0014-2999(00)00745-7","article-title":"Adenosine A(2A) receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats","volume":"408","author":"Koga","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2007.03.021_bib21","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1046\/j.1471-4159.1996.66051882.x","article-title":"Adenosine A2A receptor-mediated modulation of striatal acetylcholine release in vivo","volume":"66","author":"Kurokawa","year":"1996","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2007.03.021_bib22","doi-asserted-by":"crossref","first-page":"8038","DOI":"10.1523\/JNEUROSCI.17-20-08038.1997","article-title":"Dopamine\u2013adenosine interactions in the striatum and the globus pallidus: inhibition of striatopallidal neurons through either D2 or A2A receptors enhances D1 receptor-mediated effects on c-fos expression","volume":"15","author":"Le Moine","year":"1997","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2007.03.021_bib23","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","article-title":"Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease","volume":"15","author":"Lundblad","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejphar.2007.03.021_bib24","doi-asserted-by":"crossref","first-page":"6887","DOI":"10.1021\/jm058018d","article-title":"2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization","volume":"48","author":"Minetti","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2007.03.021_bib25","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0014-4886(03)00316-9","article-title":"Adenosine A2A antagonists: potential preventive and palliative treatment for Parkinson's disease","volume":"184","author":"Morelli","year":"2003","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejphar.2007.03.021_bib26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s100720170052","article-title":"Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease","volume":"22","author":"Morelli","year":"2001","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.ejphar.2007.03.021_bib27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.neuroscience.2003.08.010","article-title":"Normalization of glutamate decarboxylase gene expression in the entopeduncolar nucleus of rats with a unilateral 6-hydroxydopamine lesion correlates with increased GABAergic input following intermittent but not continuous levodopa","volume":"123","author":"Nielsen","year":"2004","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejphar.2007.03.021_bib28","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"1998"},{"key":"10.1016\/j.ejphar.2007.03.021_bib29","series-title":"A Stereotaxic Atlas of the Rat Brain","author":"Pellegrino","year":"1979"},{"key":"10.1016\/j.ejphar.2007.03.021_bib30","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/j.1460-9568.1996.tb01285.x","article-title":"Blockade of A2a adenosine receptors positively modulates turning behaviour and c-Fos expression induced by D1 agonists in dopamine-denervated rats","volume":"8","author":"Pinna","year":"1996","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejphar.2007.03.021_bib31","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/1098-2396(20010301)39:3<233::AID-SYN1004>3.0.CO;2-K","article-title":"Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatment in 6-hydroxydopamine-lesioned rats","volume":"39","author":"Pinna","year":"2001","journal-title":"Synapse"},{"key":"10.1016\/j.ejphar.2007.03.021_bib32","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.bbr.2006.03.021","article-title":"Expression of dyskinetic movements and turning behaviour in subchronic l-DOPA 6-hydroxydopamine-treated rats is influenced by the testing environment","volume":"171","author":"Pinna","year":"2006","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejphar.2007.03.021_bib33","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.expneurol.2003.09.001","article-title":"Ropinirole versus l-DOPA effects on striatal opioid peptide precursor in a rodent model of Parkinson's disease: implications for dyskinesia","volume":"185","author":"Ravenscroft","year":"2004","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejphar.2007.03.021_bib34","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejphar.2006.07.017","article-title":"The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-DOPA in MPTP treated common marmosets","volume":"546","author":"Rose","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2007.03.021_bib35","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.brainres.2006.10.038","article-title":"The novel adenosine A2A antagonist ST1535 potentiates the effects of a threshold dose of l-DOPA in unilaterally 6-hydroxydopamine lesioned rats","volume":"1133","author":"Rose","year":"2007","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2007.03.021_bib36","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0301-0082(98)00053-7","article-title":"Tremulous jaw movements in rats: a model of parkinsonian tremor","volume":"56","author":"Salamone","year":"1998","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ejphar.2007.03.021_bib37","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.tins.2006.09.004","article-title":"Targeting adenosine A(2A) receptors in Parkinson's disease","volume":"29","author":"Schwarzschild","year":"2006","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.ejphar.2007.03.021_bib38","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.expneurol.2004.05.027","article-title":"Blockade of adenosine A2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions","volume":"189","author":"Simola","year":"2004","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejphar.2007.03.021_bib39","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0169-328X(96)00078-2","article-title":"l-DOPA regulates glutamate decarboxylases mRNA levels in MPTP-treated monkeys","volume":"39","author":"Soghomonian","year":"1996","journal-title":"Mol. Brain Res."},{"key":"10.1016\/j.ejphar.2007.03.021_bib40","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1017\/S1461145705006188","article-title":"ST1535: a preferential A2A adenosine receptor antagonist","volume":"9","author":"Stasi","year":"2006","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.ejphar.2007.03.021_bib41","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.pharmthera.2004.10.007","article-title":"Therapeutic potential of adenosine A(2A) receptor antagonist in Parkinson's disease","volume":"105","author":"Xu","year":"2005","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2007.03.021_bib42","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0306-4522(94)00574-O","article-title":"Chronic l-DOPA treatment differentially regulates gene expression of glutamate decarboxylase, preproenkephalin and preprotachykinin in the striatum of 6-hydroxydopamine lesioned rat","volume":"66","author":"Zeng","year":"1995","journal-title":"Neuroscience"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299907003512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299907003512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T14:43:53Z","timestamp":1556289833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299907003512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":42,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["S0014299907003512"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2007.03.021","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7]]}}}